Olymviq 2mg FlexTouch is used for:

• Chronic weight management: It may be used in appropriate adults with obesity or overweight with a weight-related health condition, along with a reduced-calorie diet and increased physical activity.

• Cardiovascular risk reduction: Semaglutide may reduce the risk of major cardiovascular events in certain adults with obesity or overweight and established cardiovascular disease.

Olymviq contains Semaglutide, which activates GLP-1 receptors. It helps regulate appetite, food intake and blood sugar levels.

By slowing stomach emptying and increasing feelings of fullness, Semaglutide can reduce hunger and calorie intake. It also increases insulin release when blood sugar is high and reduces glucagon release.

Tell your doctor about all medicines, supplements and herbal products you use.

• Insulin or sulfonylureas: The risk of low blood sugar may increase when these are combined with Semaglutide.

• Oral medicines: Delayed stomach emptying can affect the absorption of some oral medicines.

• Other GLP-1 receptor agonists: Do not combine Olymviq with another Semaglutide-containing medicine or GLP-1 receptor agonist unless prescribed.

• Medicines requiring monitoring: Tell your doctor about medicines requiring regular monitoring.

• Store Olymviq 2mg FlexTouch at 2°C to 8°C in a refrigerator.

• Do not freeze.

• Do not use if frozen.

• Protect from light.

• Keep out of reach of children.

• Follow the pack instructions after first use.

Use Olymviq 2mg FlexTouch exactly as prescribed.

The 2mg/1.5mL pen can deliver 0.25mg or 0.5mg doses. It is injected under the skin once weekly into the abdomen, thigh or upper arm.

Treatment is generally started at a lower dose and increased gradually according to the treatment plan. Do not change the dose yourself.

Common side effects include 

• Nausea 

• vomiting 

• diarrhoea 

• constipation

• abdominal pain 

• decreased appetite 

• headache 

• dizziness.

Serious side effects:

• Severe or persistent abdominal pain

• Severe allergic reactions

• Persistent vomiting or diarrhoea with dehydration

• Gallstones or gallbladder inflammation

• Sudden or worsening changes in vision

• Low blood sugar when used with insulin or sulfonylureas

Seek medical attention if severe or persistent symptoms occur.

• The 2mg pen contains enough Semaglutide for multiple prescribed doses.

• It can deliver 0.25mg or 0.5mg doses as directed.

• Use Olymviq on the same day each week.

• Rotate injection sites.

• Do not increase the dose without medical advice.

• Stay adequately hydrated if vomiting or diarrhoea occurs.

• Do not share the pen or needles.